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Abstract—We have recently reported that the inhibition of the Na^/H^ exchanger (NHE) during 1 month in spontaneously 
hypertensive rats (SHR) is followed by regression of cardiomyocyte hypertrophy but not of myocardial fibrosis. The aim 
of this study was to evaluate whether a treatment of longer duration could reduce myocardial fibrosis and stiffness. SHR 
received 3.0 mg/kg per day of the specific NHE-1 inhibitor cariporide; the effect on cardiomyocyte cross-sectional area, 
myocardial collagen volume fraction, collagen synthesis, and myocardial stiffness (length-tension relation in left 
papillary muscles) was evaluated at several time points (after 1, 2, or 3 months). A slight decrease of ^5mmHgin 
systolic blood pressure was observed after 1 month of treatment with no further changes. After 2 and 3 months of 
treatment, the size of cardiomyocytes remained within normal values and myocardial fibrosis progressively decreased 
to normal level. Accordingly, myocardial stiffness and the serum levels of the carboxyterminal propeptide of 
procollagen type I, a marker of collagen type I synthesis, were normalized after 3 months. Left ventricular weight 
decreased from 910^43 (in untreated SHR) to 781^21 mg (treated SHR) after 3 months of treatment. No difference 
in body weight between treated and untreated SHR was observed after this period of treatment. The present data allow 
us to conclude that in the SHR the administration of an NHE-1 inhibitor for 2 or 3 months leads to the normalization 
of collagen type I synthesis, myocardial collagen volume fraction, and stiffness. (Hypertension. 2003;41:373-377.)
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F ibrous tissue accumulation is a feature of the structural remodeling of the myocardium seen in hypertensive heart 
disease.1 An exaggerated accumulation of collagen type I and 
type III occurs in the hypertrophied myocardium and also in 
the nonhypertrophied right ventricle and in the atria of 
animals and humans with arterial hypertension. This collagen 
accumulation has adverse effects. It results in the develop­
ment of increased myocardial stiffness that leads to diastolic 
dysfunction and ultimately to the development of systolic 
dysfunction.
Recently, a new therapeutic strategy against hypertrophy 
has emerged from the use of Na^/H^ exchanger (NHE) 
inhibitors.2–5 The inhibition of NHE-1 reduces the hypertro­
phy of the surviving myocytes after myocardial infarction3 
and of the hearts of spontaneously hypertensive rats (SHR)2 
and mice overexpressing ^1-adrenergic receptors.4 Taken 
together, these findings seem to indicate a key role of NHE 
activity in the development of myocardial hypertrophy. Even 
though our recent study showed that neither myocardial 
fibrosis nor stiffness was normalized in the SHR after 1 
month of cariporide treatment,2 the regression of fibrosis was 
observed after 6 months of NHE inhibition in another model 
of cardiac hypertrophy, the transgenic mice overexpressing 
^1-adrenergic receptors.4 Considering that the regression of 
myocyte hypertrophy and collagen accumulation might have 
different time course, the present study sought to determine 
whether a more prolonged treatment with the NHE-1 blocker 
would cause a reduction in myocardial fibrosis in the SHR 
model of cardiac hypertrophy. A possible link between 
NHE-1 activity and fibrosis may rely on the fact that the 
antiporter is a downstream effector of several fibrosis-related 
signaling systems such as transforming growth factor-^ 
(TGF^) and the renin-angiotensin-aldosterone system.6–8
Methods
Experiments were conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals (NIH publication No 85-23, 
revised 1996) with 50 male SHR and 31 normotensive Wistar (NT) 
rats (4 months old). At this age and after recording baseline body 
weight (BW) and systolic blood pressure (SBP) by the tail-cuff 
method,2 the rats were assigned to either (a) death, to assess baseline 
cardiac parameters; (b) no drug treatment or; (c) cariporide treatment 
(3.0 mg/kg per day). Baseline BW in SHR was lower than in NT10 
(mean values were 296^8 and 246^5g in NT and SHR, respective­
ly). There was no difference in BW gain during the experiment; BW 
reached 367^7, 323^9, and 325^10 g in NT, SHR, and cariporide- 
treated SHR 3 months later, respectively. Animals were euthanized 
after 1, 2, or 3 months of treatment under ether anesthesia, and their
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Baseline and Cariporide-Induced Changes in SBP, LVW, LVW/BW Ratio, and LVCVF Values
Values are mean^SEM. Numbers within parentheses indicate the number of determinations.
*P^0.05 vs age-matched untreated NT rats, one-way ANOVA; †P^0.05 vs age-matched untreated SHR rats, one-way ANOVA.
Groups
SBP, mm Hg LVW, mg
Basal 1 Month 2 Month 3 Month Basal 1 Month 2 Month 3 Month
Untreated NT 121^3 (10) 119^2 (7) 118^2 (8) 121^2 (6) 608^20 (10) 670^34 (7) 700^58 (8) 726^17 (6)
Untreated SHR 179^1 (10)* 179^1 (10)* 173^2 (5)* 180^2 (7)* 676^17 (10)* 843^20 (10)* 956^44 (5)* 910^43 (7)*
Cariporide-treated SHR 179^1 (10)* 170^2 (7)*† 168^3 (4)* 174^1 (7)*† 676^17 (10)* 717^50 (7)† 762^26 (4)† 781^21 (7)†
hearts removed. The left ventricle (LV) with the septum was 
weighed (LVW) and normalized by BW to determine cardiac 
hypertrophy.
Myocardial stiffness was determined in LV papillary muscles as 
previously described.2 Briefly, the muscles were stretched stepwise 
until the twitch-developed force reached the maximum. At each step, 
the muscle length was increased by 10% of the muscle length at zero 
resting tension (L0). The stress-strain relation of each muscle was 
fitted to an exponential equation of the form ^^A^eK^, where K 
represents the elastic stiffness constant. From each fitting, the stress 
values at given values of strain were estimated by interpolation and 
plotted as a function of strain.
Although circulating cariporide levels were not determined in our 
study, it was shown that rats treated with a similar or even lower 
dosage than ours had cariporide plasma levels higher than that 
required to inhibit NHE-1 activity by 50% in isolated cardiomyo- 
cytes.11 More importantly, our previous report demonstrated that 
doses of 0.3 mg/kg per day and 3.0 mg/kg per day induced 
antihypertrophic effects in SHR.2
Ventricular tissue was fixed in buffered 10% formaldehyde and 
paraffin-embedded. LV coronal sections (5 ^m thick) at the equator 
were stained for determining cardiomyocyte cross-sectional area 
(CSA) and quantifying collagen volume fraction (CVF) as previ­
ously described.2 To assess CSA, only round to ovoid cells with 
visible round nucleus were considered, and 50 cells were counted in 
at least 10 images obtained from each LV. CVF was calculated as the 
sum of all connective tissue areas divided by the total section 
surface, in no less than 10 images. Perivascular collagen was 
excluded from this measurement.
Serum levels of the carboxyterminal propeptide of procollagen 
type I (PIP), a marker of collagen type I synthesis, were determined 
as previously described by radioimmunoassay with a commercial 
assay kit (Orion Diagnostica).2,9 The lower detection limit (method 
sensitivity) was 1.2 ^g/L.
Statistics
Data are presented as mean^SEM. The K values of the exponential 
fitting of the stress-strain relation were used to compare stiffness in 
the papillary muscles. One-way ANOVA followed by the Student- 
Newman-Keuls post hoc test was used to assess differences between 
groups. The ANCOVA analysis was also applied to analyze the 
effect of NHE-1 inhibition on LVW, using the initial BW as the 
covariate. The significance level was set at P^0.05.
Results
The SHR used in this study had, at the beginning of the 
experiment, established hypertension with cardiac hypertro­
phy and fibrosis. The Table shows values of the variables 
studied at baseline and different time points during the 
experimental protocol. After 1 month, cariporide produced a 
slight decrease of SBP that was previously reported by us.2 
This decrease was sustained until the end of the treatment (3 
months), when SBP was ^ 5 mm Hg lower compared with 
baseline and untreated age-matched SHR.
Cariporide treatment attenuated cardiac hypertrophy in 
SHR, as shown in the Table. After 3 months of treatment, 
LVW in treated SHR was significantly lower compared with 
LVW in age-matched untreated SHR. To avoid the influence 
of the lighter BW of SHR on the appearance of the antihy- 
pertrophic effect, the LVW was normalized by BW (Table). 
LVW/BW ratio remained slightly elevated in cariporide- 
treated SHR compared with NT, although the difference did 
not reach the level of significance. In addition, an analysis of 
covariance using the starting BW as the covariate was applied 
to further address the possibility that the lighter initial BW of 
SHR would have affected the results. The analysis showed a 
statistical, highly significant difference (P^0.0001) between 
the adjusted LVW means, implying that there was not an 
overestimation of the antihypertrophic effect of NHE inhibi­
tion caused by the lighter BW of SHR.
The increased CSA of cardiomyocytes returned to a value 
within the normal range after 1 month of cariporide treatment 
(Figure 1A), and their size remained stable throughout the 
rest of the treatment. The normalization of cardiomyocyte 
size after 1 month of NHE-1 inhibition as well as the lack of 
effect on myocardial fibrosis at this time point (Figure 1B) 
were previously reported by us.2 Left ventricular collagen 
volume fraction (LVCVF) in untreated SHR was increased 
compared with age-matched NT at any time point during the 
treatment (Table). NHE-1 inhibition for 2 to 3 months 
induced a decline in myocardial fibrosis (not detected after 1 
month), so that LVCVF reached values not different from 
those found in age-matched NT rats (Figure 1B and the 
Table). The changes in serum PIP paralleled the changes in 
myocardial fibrosis: PIP levels were significantly elevated in 
untreated SHR compared with NT rats and returned to normal 
values after 2 or 3 months of cariporide treatment (Figure 1C).
Figure 2 shows representative images of the increased 
interstitial fibrosis seen in LV of SHR and the progressive 
involution to normal content induced by 2 and 3 months of 
cariporide treatment.
Muscles from hypertensive hypertrophied hearts were 
stiffer than those from NT, as denoted by the leftward shift of 
the length-tension curves shown in Figure 3A. Myocardial 
stiffness was restored to normal after 2 or 3 months of 
cariporide treatment (Figures 3B and 3C). Considered as a 
whole, the data presented herein would indicate that treatment 
with an NHE-1 inhibitor should last for more than 1 month to 
interfere with collagen synthesis, normalize myocardial col­
lagen content, and restore myocardial distensibility in SHR.
Discussion
Our results demonstrate the ability of the NHE-1 inhibitor 
cariporide to regress cardiac fibrosis in SHR with established
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Groups
LVW/BW, mg/g LVCVF, %
Basal 1 Month 2 Month 3 Month Basal 1 Month 2 Month 3 Month
Untreated NT 2.1^0.1 (10) 2.1^0.1 (7) 2.1^0.2 (8) 2.0^0.1 (6) 2.2^0.2 (4) 2.9^0.6 (4) 1.5^0.1 (4) 2.5^0.3 (4)
Untreated SHR 2.8^0.1 (10)* 2.9^0.1 (10)* 3.1^0.1 (5)* 2.8^0.1 (7)* 8.1^0.5 (4)* 8.4^1.4 (4)* 10.1^2.4 (4)* 8.5^0.3 (4)*
Cariporide-treated SHR 2.8^0.1 (10)* 2.4^0.1 (7)† 2.4^0.1 (4)† 2.4^0.1 (7)† 8.1^0.5 (4)* 8.9^1.3 (4)* 4.9^0.3 (4)† 1.2^0.3 (4)†
hypertension. The decrease in fibrous tissue was accompa­
nied by a decrease in the serologic marker of collagen type I 
synthesis, PIP. Of importance, the regression of fibrosis 
occurred in the absence of (or minimal) reduction in arterial 
pressure, indicating the hemodynamic independence of the 
mechanism. According to the regression in collagen content, 
a major determinant of tissue stiffness, there was an improve­
ment in myocardial distensibility. Even though this is the first 
demonstration of the regression of myocardial fibrosis in the 
hypertensive heart induced by NHE-1 inhibition, an effect of 
cariporide on the fibrotic hypertrophied heart of mice over­
expressing ^1 receptors has been recently reported.4
A recent study from our laboratory reported that 1 month 
of cariporide treatment induced the regression of cardiomyo­
Figure 1. Effect of NHE-1 inhibition on LV cardiomyocyte CSA 
(A), collagen volume fraction (B), and serum PIP levels (C). 
Untreated NT rats (open bar, n^4), untreated SHR (closed bar), 
and cariporide-treated SHR were studied for 1, 2, or 3 months 
(hatched bars, n^4 each). For the sake of clarity and since 
there was no significant difference between the untreated SHR 
for 1, 2, or 3 months, all data were pooled into one group, 
n^12. *P^0.05 vs other groups, 1-way ANOVA.
cyte hypertrophy in SHR without a detectable effect on 
fibrosis, myocardial stiffness, or serum PIP levels.2 The 
present study shows that extending cariporide treatment 
results in complete regression of myocardial fibrosis associ­
ated with the normalization of myocardial distensibility and 
serum PIP concentration. It has been recognized before that 
myocyte size declines, with antihypertensive therapy, more 
rapidly than the amount of collagen, a stable protein with 80 
to 120 days half-life in myocardium.12
Signaling pathways leading to myocardial fibrosis are 
complex, yet incompletely defined. Diastolic dysfunction 
accompanies those models of cardiac hypertrophy in which 
myocardial fibrosis is also present,13 but no sign of diastolic 
dysfunction has been reported in cardiac hypertrophy when 
fibrosis is absent.14 –16 Our results show that the regression of 
cardiomyocyte hypertrophy is not enough to normalize myo­
cardial distensibility. The restoration of normal distensibility 
accompanied the decline in the amount of collagen, suggest­
ing that fibrosis and not muscle mass per se is the major 
determinant of diastolic stiffness in the hypertrophied heart of 
SHR. In connection with this, the study of Brilla et al17 
showed that the reduction of collagen content and the 
improvement of diastolic dysfunction in hypertensive patients 
were independent of the regression of cardiomyocyte hyper­
trophy. Regression of myocardial fibrosis and improvement 
of diastolic distensibility after long-term interruption of the 
renin-angiotensin system were previously reported in both 
SHR and hypertensive humans.17–19
It has been proposed that myocardial stiffness is a function 
of cross-linked collagen.20 Whether NHE-1 inhibition de­
creased cross-linked collagen was not explored in this study, 
but the normalization of myocardial distensibility after cari- 
poride treatment may suggest an effect on insoluble collagen.
In our experiments we cannot exclude that changes in 
collagen degradation after NHE-1 blockade could have con-
Figure 2. Representative microphotographs of LV myocardium 
stained with the picrosirius red technique. The increased inter­
stitial fibrosis seen in untreated SHR (A) progressively returned 
to normal values after 2 (B) and 3 months (C) of cariporide treat­
ment. Magnification ^20. Bar indicates 40 ^m.
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Figure 3. Effect of chronic NHE-1 inhibition on stress-strain 
curves of LV papillary muscles from SHR. The effect was 
assessed at 3 time points of the treatment (1, 2, and 3 months: 
A, B, C, respectively). Note the leftward shift in the length­
tension relation in untreated SHR (^) compared with normoten- 
sive (NT, ^) and the progressive normalization of stiffness with 
cariporide treatment. NT (n^6); untreated SHR (pooled data 
from untreated SHR, n^9); cariporide-treated SHR for 1, 2, or 3 
months (n^4 each). *P^0.05 vs NT; †P^0.05 vs other groups, 
1-way ANOVA.
tributed to the involution of cardiac fibrosis. However, Diez 
et al19,21 have shown that fibrosis correlates best with the 
serologic marker of collagen type I synthesis.
Fibroblasts play the main role in fibrinogenesis; several 
growth factors including the TGF^ and the circulating and 
tissue components of the renin-angiotensin-aldosterone sys­
tem are potent activators of collagen synthesis in (myo)fibro- 
blasts.12,22 TGF^1 binds to membrane receptors and transmits 
signals via mitogen-activated protein kinases (MAPK)- 
dependent and Smad-dependent pathways.23 In postinfarcted 
myocardium, a condition in which NHE-1 inhibition proved 
to be beneficial,3 Smad expression is elevated and normalized 
after Angiotensin II AT1 blockade.24,25 NHE-1 is a common 
downstream effector of various of these intracellular signal­
ing mechanisms.6,7 It was reported by Takewaki et al26 that 
the inhibition of NHE-1 activity partially decreased the 
activation of MAPK and protein synthesis elicited by stretch.
Several still unanswered questions have arisen from the 
findings presented herein. How does NHE-1 inhibition reduce 
myocardial hypertrophy? Is the decrease in Na^ influx due to 
NHE-1 blockade the main mechanism? It should be kept in 
mind that the amount of Na^ entering through NHE-1 
accounts for approximately half the total Na^ influx.27 A link 
between Na^ influx by NHE and the activation of PKC-^ and 
PKC-^ isoforms in response to growth factors has been 
reported in isolated cardiomyocytes.28 ^he intracellular Na^ 
is elevated in hypertrophied myocardium,29 and Na^ has a 
direct effect on protein synthesis increase and on protein 
degradation decrease.30 Epidemiological and basic studies 
support the notion that Na^ is an independent factor for the 
development of myocardial hypertrophy.31,32 Frohlich and 
colleagues33 reported that a high Na^ diet increased not only 
cardiac enlargement in SHR but also cardiac mass in normo- 
tensive rats without detectable change of arterial pressure.
Perspectives
Clinical and epidemiological studies indicate that diastolic 
heart failure is mainly caused by hypertensive heart disease. 
It is now well recognized that it is not only the quantity but 
also the quality of the myocardium that is responsible for 
adverse cardiovascular effects in hypertensive heart disease. 
Increased fibrous tissue predisposes to an increased risk for 
diastolic and/or systolic dysfunction and, ultimately, to heart 
failure. Our findings that NHE-1 inhibition induces the 
normalization of myocardial distensibility and fibrosis— 
effects associated with a normalization of increased collagen 
synthesis—may be of particular importance for the treatment 
of hypertensive patients.
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